For most of the past decade, the conversation about GLP-1 medication has been a conversation about injections. The delivery route was assumed rather than discussed, and the questions that got attention were about eligibility, supply and cost. That assumption is now loosening, and the reason has less to do with pharmacology than with the ordinary friction of taking a medicine every week for a long time.
Oral formulations of GLP-1 and dual-receptor medications have moved from the margins of the telehealth market to something close to a standard option. Understanding why means separating three things that often get collapsed together: the molecule, the delivery route, and the routine a patient has to sustain.
Continue reading “Why oral GLP-1 formats are changing who starts treatment”






